(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)
Today's article features Aeterna Zentaris (AEZS), one of the most undervalued biotech companies in the market. This is a small $1 biotech stock which has fallen out of favor with almost all investors. A look at the chart explains why. While the broader biotech indices rallied sharply, Aeterna lost 90% of its market capitalization. This marks a widespread volatility in the sector but also enhances, as we like to elaborate in this article, the opportunity to discover deeply undervalued micro-caps. Selling of this magnitude often pushes shares down to an irrationally low level, creating huge buying opportunities. Aeterna has all...
Only subscribers can access this article, which is part of the PRO research library covering 3,609 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: